On Friday 03/17/2023 the closing price of the Abeona Therapeutics Inc Registered Shs share was $2.39 on NAS.
Compared to the opening price on Friday 03/17/2023 on NAS of $2.55, this is a drop of 6.69%.
Abeona Therapeutics Inc Registered Shs's market capitalization is $45.02 M by 17.18 M shares outstanding.
Is Abeona Therapeutics stock a Buy, Sell or Hold?
Abeona Therapeutics stock has received a consensus rating of hold. The average rating score is and is based on 1 buy ratings, 2 hold ratings, and 0 sell ratings.What was the 52-week low for Abeona Therapeutics stock?
The low in the last 52 weeks of Abeona Therapeutics stock was 2.19. According to the current price, Abeona Therapeutics is 109.13% away from the 52-week low.What was the 52-week high for Abeona Therapeutics stock?
The high in the last 52 weeks of Abeona Therapeutics stock was 9.25. According to the current price, Abeona Therapeutics is 25.84% away from the 52-week high.What are analysts forecasts for Abeona Therapeutics stock?
The 3 analysts offering price forecasts for Abeona Therapeutics have a median target of 17.00, with a high estimate of 40.00 and a low estimate of 5.00. The median estimate represents a 14.06 difference from the last price of 2.39.Abeona Therapeutics Stock Snapshot
2.41
Bid
200.00
Bid Size
2.42
Ask
400.00
Ask Size
3/17/2023
Date
8:00 PM
Time
192,886.00
Volume
2.54
Prev. Close
2.55
Open
45.02 M
Market Cap
17.18 M
Number of Shares
2.35
Day Low
2.55
Day High
2.39
2.19
52 Week Low
9.25
52 Week High
2.39
-0.34
P/E Ratio
96.60
Free Float in %
-1.92
EPS 2023
90.25
Book Value per Share
Abeona Therapeutics News More News
Abeona Therapeutics Historical Prices
Price change over selected period: 1.7%+0.04
Abeona Therapeutics Analyst Data
Total Analysts: 3
(right-click to deleteright-click to manage)(long-press to drag)
Price
Analyst: SVB Leerink
Price-Target: 5
Rating: neutral
Price-Target: 5
Rating: neutral
Analyst: Cantor Fitzgerald
Price-Target: 40
Rating: buy
Price-Target: 40
Rating: buy
Analyst: SVB Leerink
Price-Target: 6
Rating: neutral
Price-Target: 6
Rating: neutral
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 5.00
Median: 17.00
Highest: 40.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Abeona Therapeutics Analyst Opinions
Abeona Therapeutics Estimates* in USD
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Abeona Therapeutics Insider Activity
Abeona Therapeutics Dividend Calendar
*Yield of the Respective Date
Abeona Therapeutics Inc Registered Shs Calendar
Abeona Therapeutics Profile
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Moody’s Daily Credit Risk Score
Abeona Therapeutics Shareholder
| Owner | in % |
|---|---|
| Freefloat | 96.60 |
| iShares Russell 2000 ETF | 8.38 |
| Adage Capital Partners GP LLC | 7.75 |
| JPMorgan Funds - Thematics - Genetic Therapies | 7.38 |
| JPMorgan Asset Management (UK) Ltd. | 7.25 |
| D.E. Shaw & Co., Inc. | 7.16 |
| Point72 Asset Management LP | 6.70 |
| Armistice Capital LLC | 6.44 |
| EcoR1 Capital, LLC | 6.33 |
| Teachers Advisors LLC | 6.03 |
| Russell Investments Group Ltd. | 5.43 |
| Deerfield Management Co. LP | 5.06 |
| TIAA-CREF Quant Small Cap Equity Fund | 4.81 |
| GSA Capital Partners LLP | 4.59 |
| AIGH Capital Management LLC | 3.80 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.